It is likely to be at least 10 years before any new generation of antidepressants comes to market, despite evidence that depression and anxiety rates are increasing across the world, specialists said on Wednesday.
The depression drug pipeline has run dry partly due to a "failure of science" they said, but also due to big pharma pulling investment out of research and development (R&D) in the neuroscience field because the profit potential is uncertain.
"I'd be very surprised if we were to see any new drugs for depression in the next decade. The pharmaceutical industry is simply not investing in the research because it can't make money from these drugs," Guy Goodwin, a professor of psychiatry at the University of Oxford, told reporters at a London briefing.
Andrea Cipriani, a consultant psychiatrist at Oxford, said such risk aversion was understandable given uncertain returns and the approximately billion dollar cost of developing and bringing a new drug to market.
"It's a lot of money to spend, and there's a high rate of failure," Cipriani said.
Treatment for depression usually involves either medication, some form of psychotherapy, or a combination of both.
But up to half of all people treated fail to get better with first-line antidepressants, and around a third of patients are resistant to relevant medications.
DEPRESSION RATES RISING
The experts said that since the current generation of SSRI (selective serotonin reuptake inhibitors) antidepressants - including Eli Lilly's blockbuster Prozac - are widely available as cheap generics, there is reluctance among health services to fund expensive new drugs that may not be much better.
That is partly because existing medications, whilst by no means perfect, are quite effective in more than half of patients, the specialists said, and partly because in this condition in particular, placebo can have a massive impact.
That makes it difficult, they explained, to show that a new drug is working above and beyond a positive placebo response and an already effective generation of available drugs.
Depression is already one of the most common forms of mental illness, affecting more than 350 million people worldwide and ranking as the leading cause of disability globally, according to the World Health Organization.
And rates are rising. Glyn Lewis, a professor of psychiatric epidemiology at University College London, cited data for England showing a doubling in prescriptions for antidepressants in a decade, to 61 million in 2015 from 31 million in 2005.
In the United States too, more people than ever are taking antidepressants. A study in the Journal of the American Medical Association (JAMA) in 2015 found that prevalence almost doubled from 1999 to 2012, rising to 13 from 6.9 percent.
Yet several major drug companies including GlaxoSmithKline and AstraZeneca have scaled right back on neuroscience R&D in recent years, citing unfavourable risk-reward prospects.
Goodwin said the absence of a drug development pipeline was also due to lagging scientific research into what is really happening in the brains of those who do and do not respond to current antidepressants.
"It's partly a failure of science, to be frank," said Goodwin. "Scientists have to ... get more of an understanding about how these things actually work before we can then propose ways to improve them."
Reuters
Mon Jan 16 2017
![No new antidepressants in sight despite growing need, experts warn No new antidepressants in sight despite growing need, experts warn](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/http://img.astroawani.com/2017-01/51484560612_ProzacGeneric.jpg)
The experts said that since the current generation of SSRI antidepressants - including Eli Lilly's blockbuster Prozac - are widely available as cheap generics, there is reluctance among health services to fund expensive new drugs. - Filepic
AWANI 7:45 [16/07/2024] - Suspek dibawa ke lokasi | Selamat tinggal rakyat Malaysia | Harimau Malaya hilang taring?
- Polis sahkan suspek bunuh Kartini anggota polis.
- Pan-Gon enggan dedah punca letak jawatan.
- Faisal Halim sedih mentor Pan-Gon undur diri.
- Pakai reben putih di Parlimen, tak salah.
- Pan-Gon enggan dedah punca letak jawatan.
- Faisal Halim sedih mentor Pan-Gon undur diri.
- Pakai reben putih di Parlimen, tak salah.
![E-sukan harus dijadikan kepentingan sehingga ke peringkat lebih tinggi E-sukan harus dijadikan kepentingan sehingga ke peringkat lebih tinggi](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-07/61721128633_MohdHidayatMohdSa.jpg)
E-sukan harus dijadikan kepentingan sehingga ke peringkat lebih tinggi
Kerajaan juga harus wujudkan sebuah dasar yang jelas supaya kepentingan e-sukan ini mampu diperkembangkan ke masa hadapan.
![Kerajaan pandang serius penularan ideologi liberalism, pluralism Kerajaan pandang serius penularan ideologi liberalism, pluralism](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-07/61721122322_ZulkifliHasan.jpg)
Kerajaan pandang serius penularan ideologi liberalism, pluralism
Kerajaan sentiasa memandang serius terhadap penularan ideologi dan aliran pemikiran yang bercanggah dengan ajaran Islam seperti ideologi liberalism dan pluralism agama.
![Tidak dapat tidak, atlet RTG mesti bawa pulang emas - MOM Tidak dapat tidak, atlet RTG mesti bawa pulang emas - MOM](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-03/61710754100_MohdNazifuddinNaji.jpg)
Tidak dapat tidak, atlet RTG mesti bawa pulang emas - MOM
Atlet di bawah projek Road To Gold (RTG) tidak mempunyai pilihan selain memenangi emas yang diidam-idamkan Malaysia pada Sukan Olimpik 2024 di Paris.
![KEDA peruntuk RM3.37 juta tahun ini bagi keterjaminan makanan KEDA peruntuk RM3.37 juta tahun ini bagi keterjaminan makanan](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2023-09/41693913999_RubiahWang.jpg)
KEDA peruntuk RM3.37 juta tahun ini bagi keterjaminan makanan
Lembaga Kemajuan Wilayah Kedah (KEDA) memperuntukkan RM3.37 juta pada tahun ini bagi memastikan keterjaminan makanan negara.
![Dewan Rakyat lulus RUU Agensi Kawalan dan Perlindungan Sempadan Malaysia Dewan Rakyat lulus RUU Agensi Kawalan dan Perlindungan Sempadan Malaysia](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-07/41721021538_TBSHAMSUL.jpg)
Dewan Rakyat lulus RUU Agensi Kawalan dan Perlindungan Sempadan Malaysia
Rang Undang-Undang Agensi Kawalan dan Perlindungan Sempadan Malaysia 2024 yang bertujuan menubuhkan MCBA diluluskan persidangan Dewan Rakyat, hari ini.
![PAC akan mulakan prosiding isu dibangkit LKAN Siri 2/2024 PAC akan mulakan prosiding isu dibangkit LKAN Siri 2/2024](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-03/61710922383_MasErmieyatiSamsud.jpg)
PAC akan mulakan prosiding isu dibangkit LKAN Siri 2/2024
Jawatankuasa Kira-Kira Wang Negara (PAC) akan memulakan prosiding bagi empat isu yang dibangkitkan dalam Laporan Ketua Audit Negara (LKAN) Siri 2/2024.
AWANI Ringkas: Kes bunuh Nur Farah Kartini | Skandal LCS
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
ADUN Rembia sertai Pas, kenapa tak umum tahun lepas? - MP Kampar
Chong Zhemin, tindakan tersebut seolah-olah satu penghinaan paling besar kepada Parlimen yang telah meluluskan pindaan Perlembagaan Persekutuan berkait Akta Antilompat Parti.
Masuk Pas untuk sama-sama susah dengan rakyat - ADUN Rembia
Muhamad Jailani berkata, sebelum ini beliau pernah menghantar surat kepada Lembaga Disiplin UMNO memohon untuk memecat keahliannya daripada parti Melayu itu.